<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064077</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0204</org_study_id>
    <secondary_id>NCI-2012-02540</secondary_id>
    <secondary_id>CDR0000306463</secondary_id>
    <secondary_id>GOG-0204</secondary_id>
    <secondary_id>GOG-0204</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00064077</nct_id>
  </id_info>
  <brief_title>Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix</brief_title>
  <official_title>A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying four combination chemotherapy regimens using
      cisplatin to compare how well they work in treating women with stage IVB, recurrent, or
      persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel,
      vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing
      so they stop growing or die. It is not yet known which combination chemotherapy regimen
      containing cisplatin is most effective in treating cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the survival and response of patients with stage IVB, recurrent, or persistent
      carcinoma of the cervix when treated with paclitaxel and cisplatin vs vinorelbine and
      cisplatin vs gemcitabine and cisplatin vs topotecan and cisplatin.

      II. Compare the toxic effects of these regimens in these patients. III. Compare the quality
      of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 4 treatment
      arms.

      ARM I: Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours
      on day 2.

      ARM II: Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV
      over 1-4 hours on day 1.

      ARM III: Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as
      in arm II.

      ARM IV: Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.

      In all arms, treatment repeats every 21 days for 6 courses in the absence of disease
      progression or unacceptable toxicity.

      Quality of life is assessed at baseline, before courses 2 and 5, and at 9 months after study
      entry.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Overall Survival (OS)</measure>
    <time_frame>Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)</time_frame>
    <description>Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Response Using RECIST Version 1.0</measure>
    <time_frame>Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)</time_frame>
    <description>RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Progression-free Survival (PFS)</measure>
    <time_frame>Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)</time_frame>
    <description>Progression-free survival (PFS) was defined as the period from study entry until disease progression, death, or the last date of contact. Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT)-Cervical Trial Outcome of Index (FACT-Cx TOI)</measure>
    <time_frame>Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1</time_frame>
    <description>The FACT-Cx TOI is a scale for assessing general QOL of cervical cancer patients.consisting of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Cervical Cancer subscale (15 items). Each item in the FACT-Cx TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The score is calculated as the sum of the subscale scores if more than 80% of the FACT-Cx TOI items provide valid answers and all of the component subscales have valid scores. The score ranges 0-116 with a large score suggesting better QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, Assessed by Brief Pain Inventory</measure>
    <time_frame>Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1</time_frame>
    <description>Single item from the Brief Pain Inventory (BPI) assessing &quot;worst pain&quot; in the past 24 hours, on a 0-10 scale with a higher score indicating more pain than a low score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Neurotoxicity Symptoms as Measured With the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity Subscale (Short Version) (FACT/GOG-Ntx Subscale).</measure>
    <time_frame>Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1</time_frame>
    <description>The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">513</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Cervical Adenosquamous Carcinoma</condition>
  <condition>Cervical Squamous Cell Carcinoma</condition>
  <condition>Recurrent Cervical Carcinoma</condition>
  <condition>Stage IVB Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>Topotecan HCl</other_name>
    <other_name>topotecan hydrochloride (oral)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine Tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <other_name>Biovelbin</other_name>
    <other_name>Eunades</other_name>
    <other_name>KW-2307</other_name>
    <other_name>Navelbine</other_name>
    <other_name>Navelbine Ditartrate</other_name>
    <other_name>NVB</other_name>
    <other_name>Vinorelbine Ditartrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or
             adenocarcinoma of the cervix

               -  Stage IVB, recurrent, or persistent disease

          -  Not amenable to curative surgery and/or radiotherapy

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by palpation, plain x-ray, CT scan, or MRI OR at least 10 mm by
                  spiral CT scan

               -  Biopsy confirmation required if lesion is less than 30 mm

               -  Target lesion must be outside of a previously irradiated field

          -  No craniospinal metastases

          -  Performance status - GOG 0-1

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times normal

          -  Alkaline phosphatase no greater than 3 times normal

          -  AST no greater than 3 times normal

          -  Creatinine ≤ 1.2 mg/dL

          -  Creatinine &gt; 1.2 mg/dL but &lt; 1.5 mg/dL AND creatinine clearance ≥ 50 mL/min

          -  No bilateral hydronephrosis not alleviated by ureteral stents or percutaneous drainage

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No prior or concurrent malignancy within the past 5 years except nonmelanoma skin
             cancer

          -  No prior malignancy whose treatment contraindicates the current study therapy

          -  No concurrent clinically significant infection

          -  No concurrent cytokines

          -  At least 6 weeks since prior chemoradiotherapy and recovered

          -  No prior chemotherapy (except when concurrently administered with radiotherapy)

          -  At least 3 weeks since prior radiotherapy and recovered

          -  Recovered from prior surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Monk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <results_first_submitted>July 31, 2018</results_first_submitted>
  <results_first_submitted_qc>July 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2018</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From May 2003 through April 2007, 513 patients were enrolled. Interim analysis recommended early closure for futility in January 2004.</recruitment_details>
      <pre_assignment_details>Until January 2004, the study consisted of only two arms. Interim analysis recommended early closure for futility. 41 patients were enrolled until that point. These 41 patients were excluded from analysis. Two more arms were added and the study re-opened with 4 arms. The 472 patients enrolled after 1/26/2004 were included in analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Paclitaxel, Cisplatin)</title>
          <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Vinorelbine, Cisplatin)</title>
          <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
        </group>
        <group group_id="P3">
          <title>Arm III (Gemcitabine, Cisplatin)</title>
          <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="P4">
          <title>Arm IV (Topotecan, Cisplatin)</title>
          <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103">Evaluable (treatment)</participants>
                <participants group_id="P2" count="108">Evaluable (treatment)</participants>
                <participants group_id="P3" count="112">Evaluable (treatment)</participants>
                <participants group_id="P4" count="111">Evaluable (treatment)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Improper prior treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor risk</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pathology</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No tumor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Evaluable (treatment)</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Paclitaxel, Cisplatin)</title>
          <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Vinorelbine, Cisplatin)</title>
          <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Arm III (Gemcitabine, Cisplatin)</title>
          <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="B4">
          <title>Arm IV (Topotecan, Cisplatin)</title>
          <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="112"/>
            <count group_id="B4" value="111"/>
            <count group_id="B5" value="434"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="29" upper_limit="81"/>
                    <measurement group_id="B2" value="49" lower_limit="24" upper_limit="76"/>
                    <measurement group_id="B3" value="45" lower_limit="20" upper_limit="89"/>
                    <measurement group_id="B4" value="48" lower_limit="25" upper_limit="75"/>
                    <measurement group_id="B5" value="48" lower_limit="20" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="434"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="316"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Overall Survival (OS)</title>
        <description>Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.</description>
        <time_frame>Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)</time_frame>
        <population>Evaluable (treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Paclitaxel, Cisplatin)</title>
            <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vinorelbine, Cisplatin)</title>
            <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Gemcitabine, Cisplatin)</title>
            <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Topotecan, Cisplatin)</title>
            <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Overall Survival (OS)</title>
          <description>Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.</description>
          <population>Evaluable (treatment)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" lower_limit="10.02" upper_limit="16.76"/>
                    <measurement group_id="O2" value="9.99" lower_limit="8.25" upper_limit="12.25"/>
                    <measurement group_id="O3" value="10.28" lower_limit="7.62" upper_limit="11.60"/>
                    <measurement group_id="O4" value="10.25" lower_limit="8.61" upper_limit="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Response Using RECIST Version 1.0</title>
        <description>RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above.</description>
        <time_frame>Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)</time_frame>
        <population>Evaluable (treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Paclitaxel, Cisplatin)</title>
            <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vinorelbine, Cisplatin)</title>
            <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Gemcitabine, Cisplatin)</title>
            <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Topotecan, Cisplatin)</title>
            <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Response Using RECIST Version 1.0</title>
          <description>RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above.</description>
          <population>Evaluable (treatment)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease/other</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Progression-free Survival (PFS)</title>
        <description>Progression-free survival (PFS) was defined as the period from study entry until disease progression, death, or the last date of contact. Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.</description>
        <time_frame>Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)</time_frame>
        <population>Evaluable (treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Paclitaxel, Cisplatin)</title>
            <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vinorelbine, Cisplatin)</title>
            <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Gemcitabine, Cisplatin)</title>
            <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Topotecan, Cisplatin)</title>
            <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Progression-free Survival (PFS)</title>
          <description>Progression-free survival (PFS) was defined as the period from study entry until disease progression, death, or the last date of contact. Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.</description>
          <population>Evaluable (treatment)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" lower_limit="4.53" upper_limit="7.59"/>
                    <measurement group_id="O2" value="3.98" lower_limit="3.19" upper_limit="5.16"/>
                    <measurement group_id="O3" value="4.70" lower_limit="3.58" upper_limit="5.59"/>
                    <measurement group_id="O4" value="4.57" lower_limit="3.71" upper_limit="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT)-Cervical Trial Outcome of Index (FACT-Cx TOI)</title>
        <description>The FACT-Cx TOI is a scale for assessing general QOL of cervical cancer patients.consisting of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Cervical Cancer subscale (15 items). Each item in the FACT-Cx TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The score is calculated as the sum of the subscale scores if more than 80% of the FACT-Cx TOI items provide valid answers and all of the component subscales have valid scores. The score ranges 0-116 with a large score suggesting better QOL.</description>
        <time_frame>Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1</time_frame>
        <population>Patients who provided baseline and ≥ one follow-up assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Paclitaxel, Cisplatin)</title>
            <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vinorelbine, Cisplatin)</title>
            <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Gemcitabine, Cisplatin)</title>
            <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Topotecan, Cisplatin)</title>
            <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-reported Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT)-Cervical Trial Outcome of Index (FACT-Cx TOI)</title>
          <description>The FACT-Cx TOI is a scale for assessing general QOL of cervical cancer patients.consisting of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Cervical Cancer subscale (15 items). Each item in the FACT-Cx TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The score is calculated as the sum of the subscale scores if more than 80% of the FACT-Cx TOI items provide valid answers and all of the component subscales have valid scores. The score ranges 0-116 with a large score suggesting better QOL.</description>
          <population>Patients who provided baseline and ≥ one follow-up assessments</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" spread="17.6"/>
                    <measurement group_id="O2" value="69.1" spread="18.6"/>
                    <measurement group_id="O3" value="67.9" spread="19.5"/>
                    <measurement group_id="O4" value="68.1" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" spread="17.6"/>
                    <measurement group_id="O2" value="65.5" spread="15.8"/>
                    <measurement group_id="O3" value="65.3" spread="18.2"/>
                    <measurement group_id="O4" value="66.2" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="16.5"/>
                    <measurement group_id="O2" value="66.6" spread="17.4"/>
                    <measurement group_id="O3" value="64.5" spread="16.5"/>
                    <measurement group_id="O4" value="68.4" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months post cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" spread="16.6"/>
                    <measurement group_id="O2" value="69.9" spread="18.8"/>
                    <measurement group_id="O3" value="68.6" spread="19.5"/>
                    <measurement group_id="O4" value="70.9" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain, Assessed by Brief Pain Inventory</title>
        <description>Single item from the Brief Pain Inventory (BPI) assessing &quot;worst pain&quot; in the past 24 hours, on a 0-10 scale with a higher score indicating more pain than a low score.</description>
        <time_frame>Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1</time_frame>
        <population>Patients who provided baseline and ≥ one follow-up assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Paclitaxel, Cisplatin)</title>
            <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vinorelbine, Cisplatin)</title>
            <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Gemcitabine, Cisplatin)</title>
            <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Topotecan, Cisplatin)</title>
            <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Pain, Assessed by Brief Pain Inventory</title>
          <description>Single item from the Brief Pain Inventory (BPI) assessing &quot;worst pain&quot; in the past 24 hours, on a 0-10 scale with a higher score indicating more pain than a low score.</description>
          <population>Patients who provided baseline and ≥ one follow-up assessments</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.8"/>
                    <measurement group_id="O2" value="3.9" spread="3.2"/>
                    <measurement group_id="O3" value="3.3" spread="3.0"/>
                    <measurement group_id="O4" value="3.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.9"/>
                    <measurement group_id="O2" value="3.5" spread="2.8"/>
                    <measurement group_id="O3" value="3.4" spread="3.0"/>
                    <measurement group_id="O4" value="3.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.1"/>
                    <measurement group_id="O2" value="4.0" spread="2.7"/>
                    <measurement group_id="O3" value="3.5" spread="3.0"/>
                    <measurement group_id="O4" value="2.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months post cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.0"/>
                    <measurement group_id="O2" value="3.2" spread="2.9"/>
                    <measurement group_id="O3" value="3.7" spread="3.0"/>
                    <measurement group_id="O4" value="2.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Neurotoxicity Symptoms as Measured With the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity Subscale (Short Version) (FACT/GOG-Ntx Subscale).</title>
        <description>The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.</description>
        <time_frame>Baseline (pre-cycle 1), Pre-cycle 2, Pre-cycle 5, 9 months post cycle 1</time_frame>
        <population>Patients who provided baseline and ≥ one follow-up assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Paclitaxel, Cisplatin)</title>
            <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Vinorelbine, Cisplatin)</title>
            <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Gemcitabine, Cisplatin)</title>
            <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Topotecan, Cisplatin)</title>
            <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Neurotoxicity Symptoms as Measured With the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity Subscale (Short Version) (FACT/GOG-Ntx Subscale).</title>
          <description>The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.</description>
          <population>Patients who provided baseline and ≥ one follow-up assessments</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="2.9"/>
                    <measurement group_id="O2" value="13.5" spread="3.4"/>
                    <measurement group_id="O3" value="14.2" spread="2.9"/>
                    <measurement group_id="O4" value="14.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-cycle 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="3.2"/>
                    <measurement group_id="O2" value="13.3" spread="3.6"/>
                    <measurement group_id="O3" value="13.7" spread="3.5"/>
                    <measurement group_id="O4" value="14.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-cycle 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="3.5"/>
                    <measurement group_id="O2" value="13.1" spread="3.7"/>
                    <measurement group_id="O3" value="14.1" spread="3.0"/>
                    <measurement group_id="O4" value="14.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months post cycle 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="5.2"/>
                    <measurement group_id="O2" value="11.4" spread="4.7"/>
                    <measurement group_id="O3" value="12.3" spread="3.7"/>
                    <measurement group_id="O4" value="13.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every cycle while on treatment, 30 days after the last cycle of treatment , and up to 5 years in follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Paclitaxel, Cisplatin)</title>
          <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
Cisplatin: Given IV
Paclitaxel: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Vinorelbine, Cisplatin)</title>
          <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Vinorelbine Tartrate: Given IV</description>
        </group>
        <group group_id="E3">
          <title>Arm III (Gemcitabine, Cisplatin)</title>
          <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
Cisplatin: Given IV
Gemcitabine Hydrochloride
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
        <group group_id="E4">
          <title>Arm IV (Topotecan, Cisplatin)</title>
          <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
Cisplatin: Given IV
Quality-of-Life Assessment: Ancillary studies
Topotecan Hydrochloride: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Transfusion Prbc's</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis Embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ischemia/Cardiac Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cardiac Left Ventricular Function</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diarrhea Without Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fistula Rectal/Anal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diarrhea With Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fistula Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Gi Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fever(No Neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pain Rectal/Perirectal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pain Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile With Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infection Without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infection With Grade 3/4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infection No Anc</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Catheter-Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infection Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Metabolic Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia(Incoordination)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cns Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ureteral Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Renal/Gu Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Genitourinary/Renal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pulmonary Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Skin Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Prothrombin Time</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hemorrhage With Grade 3/4 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Melena/Gi Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vaginal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding/Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="106" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Otherhematologic</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Lymphatics</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis Embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Cardiac Left Ventricular Function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner Ear/Hearing</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Hearing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Stomatitis/Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Constitutional</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile With Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Infection Without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy Sensor</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Otherneurologic</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Genitourinary/Renal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual/Reproductive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Rash Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Other Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Kuras on behalf of Michael Sill and Helen Huang</name_or_title>
      <organization>NRG Oncology</organization>
      <phone>716-845-5702</phone>
      <email>kurasa@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

